Replacement therapy for bleeding episodes in factor VII deficiency

Summary

Patients with inherited factor VII (FVII) deficiency display different clinical phenotypes requiring ad hoc management. This study evaluated treatments for spontaneous and traumatic bleeding using data from the Seven Treatment Evaluation Registry (STER). One-hundred one bleeds were analysed in 75 patients (41 females; FVII coagulant activity <1–20%). Bleeds were grouped as haemarthroses (n=30), muscle/subcutaneous haematomas (n=16), epistaxis (n=12), gum bleeding (n=13), menorrhagia (n=16), central nervous system (CNS; n=9), gastrointestinal (GI; n=2) and other (n=3). Of 93 evaluable episodes, 76 were treated with recombinant, activated FVII (rFVIIa), eight with fresh frozen plasma (FFP), seven with plasma-derived FVII (pdFVII) and two with prothrombin-complex concentrates. One-day replacement therapy resulted in very favourable outcomes in haemarthroses, and was successful in muscle/subcutaneous haematomas, epistaxis and gum bleeding. For menorrhagia, single- or multiple-dose schedules led to favourable outcomes. No thrombosis occurred; two inhibitors were detected in two repeatedly treated patients (one postrFVIIa, one post-pdFVII). In FVII deficiency, most bleeds were successfully treated with single ‘intermediate’ doses (median 60 µg/kg) of rFVIIa. For the most severe bleeds (CNS, GI) short- or long-term prophylaxis may be optimal.

Keywords

Bleeds - replacement therapy - factor VII deficiency

• References

• 1 Mannucci PM, Duga S, Peyvandi F. Recessively inherited coagulation disorders. Blood 2004; 104: 1243-1252.
• 2 Mariani G, Bernardi F. Factor VII deficiency. Semin Thromb Hemost 2009; 35: 400-406.
• 3 Mariani G, Dolce A. Congenital factor VII deficiency. In: Textbook of Hemophilia. Wiley-Blackwell: 2010. pp. 341-347.
• 4 Perry DJ. Factor VII Deficiency. Br J Haematol 2002; 118: 689-700.
• 5 Borhany M, Pahore Z, Ul Qadr Z. et al. Bleeding disorders in the tribe: result of consanguineous in breeding. Orphanet J Rare Dis 2010; 05: 23.
• 6 Bernardi F, Dolce A, Pinotti M. et al. Major differences in bleeding symptoms between factor VII deficiency and hemophilia B. J Thromb Haemost 2009; 07: 774-779.
• 7 Mariani G, Herrmann FH, Dolce A. et al. Clinical phenotypes and factor VII genotype in congenital factor VII deficiency. Thromb Haemost 2005; 93: 481-487.
• 8 Mariani G, Testa MG, Di Paolantonio T. et al. Use of recombinant, activated factor VII in the treatment of congenital factor VII deficiencies. Vox Sang 1999; 77: 131-136.
• 9 Mariani G, Konkle BA, Ingerslev J. Congenital factor VII deficiency: therapy with recombinant activated factor VII -- a critical appraisal. Haemophilia 2006; 12: 19-27.
• 10 Mariani G, Dolce A, Batorova A. et al. Recombinant, activated factor VII for surgery in factor VII deficiency: a prospective evaluation - the surgical STER. Br J Haematol 2011; 152: 340-346.
• 11 Mariani G, Dolce A, Napolitano M. et al. Invasive procedures and minor surgery in factor VII deficiency. Haemophilia 2012; 18: e63-e65.
• 12 Ingerslev J, Christiansen K, Sorensen B. Inhibitor to factor VII in severe factor VII deficiency: detection and course of the inhibitory response. J Thromb Haemost 2005; 03: 799-800.
• 13 Kessler C, Mariani G. Clinical manifestations and therapy of the hemophilias. In: Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Lippincott Williams & Wilkins; 2006
• 14 Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med 1994; 236: 391-399.
• 15 Hallberg L, Hulthen L, Bengtsson C. et al. Iron balance in menstruating women. Eur J Clin Nutr 1995; 49: 200-207.
• 16 Ragni MV, Lewis JH, Spero JA. et al. Factor VII deficiency. Am J Hematol 1981; 10: 79-88.
• 17 Morfini M, Martinowitz U, Batorova A. et al. Pharmacokinetics of FVII. Blood. 2011 118. Abstract E2259